Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)

• DOI: 10.1007/s00277-017-3150-3
• Publication Date: 2017-10-31T15:05:56Z
• Authors: Gabriele Nagel; D. Weber; E. Fromm; S. Erhardt; M. Lübbert; W. Fiedler; T. Kindler; J. Krauter; P. Brossart; A. Kündgen; H. R. Salih; J. Westermann; G. Wulf; B. Hertenstein; M. Wattad; K. Götze; D. Kraemer; T. Heinicke; M. Girschikofsky; H.G. Derigs; H. A. Horst; C. Rudolph; M. Heuser; G. Göhring; V. Teleanu; L. Bullinger; F. Thol; V. I. Gaidzik; P. Paschka; K. Döhner; A. Ganser; Hartmut Döhner; R. F. Schlenk
• Keywords: Adult; Aged, 80 and over; Male; Cancer Research; Adolescent; 610; Middle Aged; 3. Good health; Leukemia, Myeloid, Acute; 03 medical and health sciences; 0302 clinical medicine; fms-Like Tyrosine Kinase 3; Austria; Germany; Mutation; Humans; Original Article; Female; Registries; Aged

We describe genetic and clinical characteristics of acute myeloid leukemia (AML) patients according to age from an academic population-based registry. Adult with newly diagnosed AML at 63 centers in Germany Austria were followed within the AMLSG BiO registry (NCT01252485). Between January 1, 2012, December 31, 2014, data 3525 (45% women) collected. The median was 65 years (range 18-94). comparison age-specific incidence rates epidemiological cancer registries revealed excellent coverage < 70 old good up 80. distribution European LeukemiaNet (ELN) risk categorization 2010 20% favorable, 31% intermediate-1, 28% intermediate-2, 21% adverse. With increasing age, relative but not absolute prevalence ELN favorable intermediate-1 (p 0.001), activating FLT3 mutations ECOG performance status 2 HCT-CI comorbidity index 3 0.001) decreased. Regarding treatment, obesity associated intensive whereas adverse risk, higher > 0 non-intensive treatment or best supportive care. provides reliable distributions genetic, clinical, age.